Scholarlink

Objective <p>To evaluate the effects of prophylactic hydrocortisone (pHCT) on the odds of death or moderate to severe bronchopulmonary dysplasia (BPD) in preterm neonates.</p> Study design <p>Multi-center retrospective cohort study of infants born &lt;28 weeks in the Canadian Neonatal Network 2019–2023 who received pHCT with 1:1 propensity score-matched controls. Hierarchical composite endpoints were explored using win odds analyses.</p> Results <p>There were 361 infants per group with balanced baseline characteristics. There were no differences in the odds of death or moderate to severe BPD (pHCT 259/361 [71.8%] vs. control 264/361 [73.1%], OR 0.92, 95% CI [0.68, 1.24]). Win odds (95% CI) were not different: 1.02 (0.85, 1.28). There was lower use of systemic postnatal steroids and treatment of patent ductus arteriosus in the pHCT group; no significant differences in other safety outcomes were observed.</p> Conclusions <p>pHCT was not associated with reductions in mortality nor moderate to severe BPD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Assessing the real-world effects of prophylactic hydrocortisone in the Canadian Neonatal Network: A cohort study

  • 期刊论文

  • 发表日期：

    2026年7月1日

查看全文
  • Marisa de Souza,
  • Marc Beltempo,
  • Bernard Thébaud,
  • Yi-Chen Su,
  • Brooke Read,
  • Amit Mukerji,
  • Brigitte Lemyre

摘要

Objective

To evaluate the effects of prophylactic hydrocortisone (pHCT) on the odds of death or moderate to severe bronchopulmonary dysplasia (BPD) in preterm neonates.

Study design

Multi-center retrospective cohort study of infants born <28 weeks in the Canadian Neonatal Network 2019–2023 who received pHCT with 1:1 propensity score-matched controls. Hierarchical composite endpoints were explored using win odds analyses.

Results

There were 361 infants per group with balanced baseline characteristics. There were no differences in the odds of death or moderate to severe BPD (pHCT 259/361 [71.8%] vs. control 264/361 [73.1%], OR 0.92, 95% CI [0.68, 1.24]). Win odds (95% CI) were not different: 1.02 (0.85, 1.28). There was lower use of systemic postnatal steroids and treatment of patent ductus arteriosus in the pHCT group; no significant differences in other safety outcomes were observed.

Conclusions

pHCT was not associated with reductions in mortality nor moderate to severe BPD.